Linezolid optic neuropathy

H. Victoria Miller, Angela A. Cao, Collin M. McClelland, Michael S. Lee

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewIn this article, we reviewed 67 reported cases of linezolid optic neuropathy and describe the common characteristics and expectations for recovery with an emphasis on recent findings in the literature.Recent findingsLinezolid classically causes a reversible, duration-dependent optic neuropathy. However, in our review, we found only 66.7% of patients recovered complete visual function. Vision loss most commonly affected visual acuity followed by visual field and color vision. We also found patients taking higher doses of linezolid experienced full recovery less often, suggesting a dose-dependent component of linezolid optic neuropathy. Linezolid use has increased in frequency and duration, especially in the treatment of drug-resistant tuberculosis, and data indicate that these patients experience lower rates of complete vision recovery compared with patients taking linezolid for other indications.SummaryLinezolid is an effective medication for treating drug-resistant infections; however, it may result in optic neuropathy. It is reasonable for patients on linezolid to undergo screening examinations, especially those on higher doses or for prolonged duration of therapy.

Original languageEnglish (US)
Pages (from-to)481-486
Number of pages6
JournalCurrent Opinion in Ophthalmology
Issue number6
StatePublished - Nov 1 2023

Bibliographical note

Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.


  • drug-resistant tuberculosis
  • linezolid
  • toxic optic neuropathy

PubMed: MeSH publication types

  • Review
  • Journal Article


Dive into the research topics of 'Linezolid optic neuropathy'. Together they form a unique fingerprint.

Cite this